Business Context and Reporting Period
Company: StemCells, Inc. (Note: Request metadata listed "Microbot Medical Inc.", but the filing text identifies the registrant as StemCells, Inc.)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2011
Business Overview: A biopharmaceutical company focused on researching, developing, and commercializing stem cell therapeutics (specifically HuCNS-SC cells for CNS disorders) and enabling tools for stem cell research. The company has incurred significant operating losses since inception and relies on external financing to fund operations.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Total Revenue | $221,467 | $230,273 |
| Gross Profit | $166,943 | $186,511 |
| Net Loss | $(5,747,235) | $(6,124,075) |
| Net Loss Per Share (Basic/Diluted) | $(0.04) | $(0.05) |
| Cash and Cash Equivalents (End of Period) | $13,066,185 | $31,336,987 |
| Marketable Securities (Current) | $8,556,966 | $190,804 |
| Total Assets | $32,246,806 | $30,601,573 |
| Total Liabilities | $12,200,190 | $15,120,944 |
| Stockholders' Equity | $20,046,616 | $15,480,629 |
Debt and Liquidity: The company holds approximately $656,250 in bonds payable and capital lease obligations. Liquidity is supported by cash reserves and recent equity financing, though the company expects to incur additional operating losses in the foreseeable future.
Material Changes vs. Prior Period
- Revenue: Total revenue decreased slightly by 4% ($8,806) compared to Q1 2010. This was driven by a 37% decrease in licensing and grant revenue ($41,757 decline), partially offset by a 28% increase in product sales ($32,951 increase) due to new product launches.
- Operating Expenses: Total operating expenses decreased by 1% ($111,048). Research and Development (R&D) expenses increased by 10% ($488,163) due to higher clinical trial and facility costs. Selling, General, and Administrative (SG&A) expenses decreased by 20% ($509,013), primarily due to reduced legal fees and lower stock-based compensation.
- Net Loss: Net loss improved by approximately $377,000 compared to the prior year, largely due to a non-cash gain of $1,782,955 from the change in fair value of warrant liability.
- Cash Flow: Net cash used in operating activities decreased by 5% to $7.4 million. Net cash used in investing activities increased significantly to $8.4 million, primarily due to the purchase of $8.4 million in marketable securities. Net cash provided by financing activities increased to $9.1 million, driven by a $9.4 million equity offering in January 2011.
Guidance, Outlook, and Risks
- Clinical Progress: In April 2011, the company initiated a Phase I/II clinical trial in Switzerland for chronic spinal cord injury. Patient accrual for the Phase I trial in Pelizaeus-Merzbacher Disease (PMD) was completed in February 2011. However, the Phase Ib trial for Neuronal Ceroid Lipofuscinosis (NCL) was terminated in April 2011 due to lack of patient accrual.
- Cost Reduction: In May 2011 (subsequent event), the company eliminated 20 full-time positions, expecting annual expense reductions of approximately $2.3 million and a one-time severance charge of $300,000 in Q2 2011.
- Capital Needs: Management states the company has limited liquidity and must obtain significant additional capital to sustain product development, clinical trials, and operations. There is no assurance that financing will be available on acceptable terms.
- Listing Status: The company received notice from NASDAQ that its stock price had fallen below $1.00 for 30 consecutive days. It has 180 days (until August 30, 2011) to regain compliance or face delisting.
- Legal Contingencies: Ongoing patent infringement litigation against Neuralstem, Inc. remains a material contingency. The company has capitalized $700,000 to offset litigation costs against future royalty payments to NeuroSpheres.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of current cash ($13.1M) and marketable securities ($8.6M) against projected burn rates, especially given the expectation of continued losses.
- NASDAQ Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement for 10 consecutive days before the August 30, 2011 deadline to avoid delisting.
- Financing Capability: Assess the company's ability to raise additional capital given the current market conditions and the recent equity offering at $1.00/share.
- Clinical Trial Viability: Review the implications of the terminated NCL trial and the progress of the new spinal cord injury trial in Switzerland.
- Warrant Liability Volatility: Note that a significant portion of the net loss reduction ($1.8M) was a non-cash gain from warrant liability revaluation, which is highly sensitive to stock price volatility.